HistoSonics received CE Mark approval for its Edison® Histotripsy platform, enabling access and commercialization across Europe. The company said this regulatory milestone is accelerating its global commercialization efforts, which should improve potential market access versus prior limitations.
HistoSonics received CE Mark approval for its Edison® Histotripsy platform, enabling access and commercialization across Europe. The company said this regulatory milestone is accelerating its global commercialization efforts, which should improve potential market access versus prior limitations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
